Novo Nordisk(US:NVO) Financial Modeling Prep·2026-01-22 21:03Group 1 - Novo Nordisk is recognized for its leadership in diabetes care and chronic diseases, with Goldman Sachs maintaining a "Buy" rating and raising the price target to DKK 436 from DKK 352, reflecting confidence in future performance [1][5] - The collaboration with Sesame to launch the Wegovy® pill is a strategic move to expand Novo Nordisk's product portfolio and enhance its position in the healthcare sector [2][5] - The current stock price of Novo Nordisk is $62.34, showing a 5.09% increase, with a trading range today between $61.04 and $62.36, indicating market volatility [3][5] Group 2 - Novo Nordisk's market capitalization is approximately $277.1 billion, highlighting its significant presence in the global healthcare market [4][5] - The trading volume for Novo Nordisk on the NYSE is 9,088,532 shares, indicating active investor interest and close monitoring of the company's developments [4][5]